CREATING A HEALTHIER WORLD FOR ALL PEOPLE: THE GILEAD BENELUX NARRATIVE
DELIVERING ON OUR GLOBAL VISION AND MISSION
vision: make the world a healthier place for all people. mission: discover, develop and deliver innovative therapies for people with life-threatening diseases.
What began in the late 1980's as a bold response to the AIDS crisis evolved into Gilead Sciences:
A relentless force against the world’s most serious diseases, whose work over nearly 40 years has improved the health of millions with diseases and conditions including cancer, viral hepatitis, HIV, inflammation, and COVID-19.
A global biopharmaceutical leader with 25+ currently marketed therapies and more than 17,600 employees, including some of the world’s foremost researchers, scientists and clinicians.
We are united in our commitment to improving the lives of patients. We are guided by our core values — integrity, inclusion, teamwork, excellence, and accountability.
Our leadership commitments > I care, I trust, I listen, I own, I am bold - shape how we lead and work together.
With grit and passion, we focus on delivering innovation and expanding access to care.
We navigate our environment with agility and purpose, active listening and collaboration, to advance innovation and patient access to our treatments.
We believe that a healthier world is only possible when everyone feels empowered to thrive.
THERAPEUTIC AREAS: DRIVING ADVANCEMENTS IN VIROLOGY,
ONCOLOGY, AND INFLAMMATION
Gilead is advancing science across virology, oncology, and inflammation. We have 25+ marketed therapies, and the most robust and diverse pipeline in our history with 60 investigational products involving over 50 clinical programs, including 15 Phase 3 and 13 Phase 2 trials.
Virology
Gilead’s therapies have helped set new standards in HIV and viral hepatitis care, offering durable disease control and better outcomes for patients.
Our research explores new ways to fight viruses — targeting replication, restoring immune function, and developing therapies that can be rapidly deployed in future pandemics.
Oncology
Our cancer therapies are bringing new options to patients with difficult-to-treat cancers.
We’re expanding into solid tumors and combination treatments, guided by research that targets key genetic drivers of cancer and the immune system’s role in fighting them.
Through Kite, the global leader in cell therapy, we’re accelerating innovation and expanding access to personalized cancer care.
Inflammation
Our inflammation portfolio focuses on serious immunerelated diseases, including rare liver diseases and systemic disorders that affect multiple parts of the body.
Current therapies reflect our precision approach to targeting the immune system, while pipeline candidates aim for greater specificity and durability. We continue to advance this area through strategic partnerships and in-house innovation.
GILEAD’S LEGACY OF FIRSTS AND TRANSFORMATIONS
For nearly 40 years, Gilead has been at the forefront of tackling some of the world’s greatest public health challenges.
We helped transform HIV into a treatable, preventable, chronic condition for millions of people.
We developed the first cure for hepatitis C, helping to heal millions worldwide.
We developed the first and only treatment for hepatitis delta (HDV) and the first treatment for primary biliary cholangitis (PBC), a chronic autoimmune liver disease.
We developed the first antiviral for COVID-19, helping to reduce the burden of the pandemic for tens of millions of people worldwide.
Our antibody-drug conjugate was the first ADC in its class to show meaningful survival benefit in two different types of metastatic breast cancer (mBC).
We transformed the cancer treatment landscape with our cutting-edge oncology portfolio.
Our WHO-designated essential antifungal treatment has been saving lives in resource-limited settings since 2010.
And we’re not done. Gilead is working to cure more viral diseases and certain cancers, while leading the charge to end the HIV epidemic.
GILEAD BENELUX: TRANSLATING GLOBAL PURPOSE
INTO LOCAL IMPACT
Gilead BENELUX is a vital part of the Gilead journey translating global purpose into local impact.
BE-UNB-1749 - Last updated: March 2026 - For Internal Use Only
Gilead BENELUX is part of Gilead Sciences, a U.S.-based global biopharmaceutical company that for nearly 40 years has been discovering, developing and delivering innovative therapies for HIV, liver diseases, COVID-19 and cancer.
Established 20 years ago, Gilead BENELUX is strategically located in a region known for innovation and collaboration.
With around 1,000 colleagues, we work from our offices in Amsterdam and Brussels and our Kite CAR T manufacturing site near Amsterdam.
Our team of around 100 at Gilead BENELUX, and 900 at our Kite CAR T manufacturing site — is a blend of scientific precision, collaborative energy, and empathy.
Driven by our company’s vision to make the world a healthier place for all, we contribute to our global strategy through R&D, clinical trials, manufacturing, and initiatives that advance patient access, community partnerships, and meaningful engagement.
Across the Benelux, our portfolio includes 25+ Gilead therapies — spanning HIV, liver diseases, COVID-19 and cancer — and we are involved in over 50 clinical studies within our therapeutic areas.
GILEAD BENELUX: ADVANCING GILEAD INNOVATION
AND IMPACT
For 20 years and counting, BENELUX has helped accelerate innovation, expand access, and strengthen healthcare systems contributing to the region’s reputation as an established biotech innovation hub, with a thriving life sciences ecosystem.
BE-UNB-1749 - Last updated: March 2026 - For Internal Use Only
We help expand access to life-saving HIV and hepatitis therapies across Belgium, the Netherlands, and Luxembourg — supporting national efforts to end these epidemics.
We advance CAR T-cell therapy research and manufacturing with our Hoofddorp-based Kite manufacturing facility near Amsterdam.
We partnered with national authorities and hospitals to ensure timely access to Gilead’s pioneering COVID-19 antiviral therapy, and support pandemic preparedness and equitable care. We foster scientific collaboration and clinical research, partnering with leading universities and hospitals to drive progress in virology, oncology, and immunology.
BE-UNB-1749 - Last updated: March 2026 - For Internal Use Only
ACCESS AND HEALTH EQUITY: PROGRESS THROUGH PARTNERSHIPS
At Gilead, we define the value of our medicines by the impact they have on patients and society. We advance global health through equitable access, inclusive research, and responsible production.
For example, we:
Support underserved and underresourced communities through strategic partnerships and impactful programs across HIV, oncology, and public health.
Strengthen health systems through global programs that promote education, health resources, and financial support.
Price medicines to reflect the value they deliver to patients, healthcare systems and society.
Expand access in resource-limited settings through voluntary licensing — making therapies available across HIV, viral hepatitis, and COVID-19.
Provide philanthropic support — as one of the world’s leading funders of HIV initiatives, we’ve also awarded more than $35 million in oncology grants.
Advance inclusive research and embed DEI (Diversity, Equity, and Inclusion) principles across our workforce and through community engagement.
Uphold environmental stewardship — setting ambitious goals and nearing 100% renewable electricity
Maintain strict environmental standards across our manufacturing and R&D facilities.
BEYOND MEDICINE: WE DON’T JUST WORK IN THE BENELUX — WE
SHOW UP FOR IT
Gilead cares deeply about making a difference in the world through its work and its employees, who live their purpose: to make a positive impact in the communities we serve.
We champion health equity and community engagement, working with local stakeholders to reduce stigma and improve outcomes for vulnerable populations.
From HIV outreach in Suriname (northern South America), to STD prevention in Brussels, our grant and fellowship programs empower NGOs (Non-Governmental Organizations), hospitals, universities, and advocacy groups to expand access and elevate education for underserved communities and healthcare professionals.
We work with public health authorities and NGOs to promote early testing for HIV, hepatitis B, and hepatitis C.
We co-create with communities to build health equity — from the Here We Are HIV magazine to TNBC (TripleNegative Breast Cancer) events and hepatitis screening campaigns.
We ensure diverse representation in clinical trials.
Our Kite Amsterdam CAR T facility operates with a zero carbon footprint.
We act locally — planting trees, cleaning rivers, and championing sustainability and health equity as part of our everyday culture.
OUR FUTURE: ACCELERATING THE NEXT WAVE OF BREAKTHROUGHS
Gilead is shaping the future of medicine with its strongest, most diverse pipeline to date and a growing portfolio of marketed therapies. Through bold internal discovery and strategic partnerships, we aim to deliver 10 + transformative medicines by 2030.
- Last updated: March 2026 - For Internal Use Only
How to implement our objectives in:
Accelerating Development & Delivery
Advancing therapies from early discovery to market with speed and precision.
Pioneering combination therapies and new delivery modes across therapeutic areas.
Over 50 clinical programs underway.
How
to implement our objectives in:
Expanding Impact Across Core Areas
Providing alternative HIV prevention options.
Leading the most comprehensive HIV cure program, with confidence in achieving the first functional cure.
Pursuing cures for HBV (hepatitis B virus) and HDV, and investing in pandemic preparedness and emerging virology.
Transforming oncology with Kite and exploring promising new targets.
Growing our inflammation portfolio through partnerships and in-house immunology expertise.
How to implement our objectives in:
Powerful Partnerships Driving Progress
Collaborating across industry, academia, advocacy, and policy to meet diverse patient needs. Sharing insights and accelerating HIV cure research through global partnerships.
Strengthening oncology R&D through approximately 40 strategic collaborations since 2019.
Gilead BENELUX is proud to help advance our company’s global strategy through innovation, partnerships, and the delivery of breakthrough solutions for patients. BE-UNB-1749 - Last updated: March 2026 - For Internal Use Only
FOR FURTHER INFORMATION CONTACT
For further information contact your Gilead Sciences BENELUX Public Affairs colleagues.
-